Nasdaq

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and ...
Mena FN

QED Group And The Georgetown Strategy Group Launch Q2 Impact

ARLINGTON, Va., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Neelima Grover, Chief Executive Officer of QED Group LLC and President/Chief Executive Officer of QED Holdings, and Dave Harden, Managing Director of ...
Business Insider

QED Group CEO Neelima Grover to Speak at NABOE CEO Breakfast Series

ARLINGTON, Va., Sept. 11, 2018 /PRNewswire/ -- The QED Group and the National Association of Business Owners and Entrepreneurs (NABOE) have announced that QED's CEO Neelima Grover will speak at their ...
Business Wire

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

PALO ALTO, Calif. & LUGANO, Switzerland--(BUSINESS WIRE)--BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and ...